Press-release for stocks for pfe listed in the nasdaq exchange

symbols : Pfe exchanges : Nasdaq

save search

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Published: 2024-03-18 (Crawled : 21:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -8.3% | O: -0.18% H: 0.4% C: -0.14%
ARVN | $34.3 2.54% 2.48% 800K

Health Technology

| -21.5% | O: -3.22% H: 4.58% C: 3.23%
medical

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -10.4% | O: -0.21% H: 0.11% C: -1.06%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 2.23% | O: 0.9% H: 2.03% C: 1.89%
VERU | $1.42 22.41% 18.31% 7M

Health Technology

| 76.29% | O: -0.53% H: 2.22% C: -3.59%
ALT | $6.9 -1.99% -2.03% 3.2M

Commercial Services

| -23.81% | O: 0.3% H: 11.41% C: 9.8%
medical program

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Published: 2024-03-07 (Crawled : 12:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -6.51% | O: 0.04% H: 0.44% C: -1.51%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| -9.31% | O: -2.08% H: 0.13% C: -0.57%
BMY | $48.3 0.96% -0.1% 11M

Health Technology

| -9.59% | O: 0.36% H: 0.34% C: -0.54%
XFOR | $1.195 0.0% 1.7M

Health Technology

| 24.55% | O: 0.12% H: 0.0% C: -4.98%
EYPT | $17.49 -16.48% -19.73% 4.1M

Health Technology

| -15.15% | O: 2.56% H: 1.37% C: -4.13%
AQST | $4.505 14.92% 12.99% 5.8M

Health Technology

| -23.46% | O: 1.79% H: 12.3% C: 10.94%
ALKS | $23.78 -0.96% -0.97% 1.8M

Health Technology

| -16.66% | O: 1.11% H: 0.96% C: 0.65%

Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
Published: 2024-03-06 (Crawled : 01:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -2.53% | O: 3.14% H: 1.49% C: 1.08%
KZR | $0.7896 -3.31% -3.42% 540K

Health Technology

| -20.39% | O: 1.94% H: 0.0% C: -1.9%
financial results

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -6.48% | O: -0.22% H: 0.29% C: -0.85%
ARVN | $34.3 2.54% 2.48% 800K

Health Technology

| -31.46% | O: 0.0% H: 1.25% C: -1.6%
year update financial results

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -8.43% | O: -0.32% H: 0.0% C: -1.77%
TNXP | $0.1549 -2.82% -2.91% 1.4M

Health Technology

| -50.31% | O: 4.32% H: 7.17% C: 2.5%
drug fibromyalgia study

BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -5.75% | O: 0.15% H: 0.59% C: 0.37%
therapeutics

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -5.75% | O: 0.15% H: 0.59% C: 0.37%
ARVN | $34.3 2.54% 2.48% 800K

Health Technology

| -30.0% | O: -1.09% H: 5.61% C: 4.49%
first breast cancer trial therapeutics advanced

Orphan Drugs Market Projection: BCC Research Anticipates a Staggering $415.2 Billion Valuation by 2028, Reflecting Soaring Global Demand
Published: 2024-02-09 (Crawled : 10:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K

Health Technology

| -12.38% | O: -0.91% H: 3.88% C: 3.88%
AZNCF | $140.15 -4.19% 560

Health Technology

| 8.24% | O: -2.6% H: 2.26% C: 1.44%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -9.35% | O: -2.46% H: 0.0% C: 0.0%
ALPMY | $9.46 -1.11% 500K

Manufacturing

| -12.95% | O: 4.66% H: 0.0% C: -3.92%
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -7.8% | O: -0.04% H: 0.11% C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| -8.17% | O: -0.37% H: 0.21% C: 0.05%
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| -6.02% | O: 0.33% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| 0.04% | O: 1.11% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M

Health Technology

| 7.47% | O: -1.28% H: 1.05% C: -0.72%
research global market

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Published: 2024-02-06 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -4.33% | O: 0.34% H: 3.99% C: 3.15%
ARVN | $34.3 2.54% 2.48% 800K

Health Technology

| -27.78% | O: 0.91% H: 5.05% C: 4.9%
arv-471 fda breast cancer treatment designation

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
GNMSF | $281.02 3.83% 210

Health Technology

| 0.08% | O: -0.78% H: 0.3% C: -0.84%
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -6.85% | O: -0.4% H: 0.07% C: -0.92%
GMAB | $28.32 -0.74% -0.74% 240K

Health Technology

| 1.28% | O: -1.21% H: 0.72% C: -0.11%
authorization cancer treatment application

Global Sustained Release Coatings Markets, 2018-2022 and 2023-2028: Growing Demand for Controlled Drug Delivery Boosts Expansion
Published: 2024-02-01 (Crawled : 17:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| -1.68% | O: -1.29% H: 0.0% C: -1.38%
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -6.13% | O: 0.07% H: 0.83% C: 0.7%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| -10.04% | O: 1.55% H: 0.79% C: 0.25%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| 0.41% | O: 1.27% H: 1.87% C: 1.73%
EMN | $96.02 0.05% 0.0% 680K

Process Industries

| 15.38% | O: 0.79% H: 0.8% C: 0.77%
drug expansion global growing

Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-31 (Crawled : 02:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K

Health Technology

| -16.94% | O: 4.34% H: 0.0% C: 0.0%
ALPMY | $9.46 -1.11% 500K

Manufacturing

| -19.27% | O: 0.0% H: 1.38% C: 0.26%
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -5.92% | O: 0.56% H: 1.25% C: -0.33%
keytruda drug japan bladder cancer treatment application advanced

Astellas Announces Strategic Collaboration with Mass General Brigham
Published: 2024-01-30 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K

Health Technology

| -16.94% | O: 4.34% H: 0.0% C: 0.0%
ALPMY | $9.46 -1.11% 500K

Manufacturing

| -19.27% | O: 0.0% H: 1.38% C: 0.26%
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -5.92% | O: 0.56% H: 1.25% C: -0.33%
collaboration

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
Published: 2024-01-30 (Crawled : 12:30) - biospace.com/
GNMSF | $281.02 3.83% 210

Health Technology

| 1.86% | O: 2.14% H: 1.03% C: -0.89%
ALPMF | $9.594 43.47% 2.2K

Health Technology

| -15.47% | O: 1.76% H: 0.0% C: 0.0%
ALPMY | $9.46 -1.11% 500K

Manufacturing

| -19.48% | O: -3.53% H: 3.49% C: 3.4%
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -7.5% | O: 1.49% H: 1.72% C: -3.12%
GMAB | $28.32 -0.74% -0.74% 240K

Health Technology

| 0.85% | O: 0.42% H: 0.04% C: -0.99%
ARVN | $34.3 2.54% 2.48% 800K

Health Technology

| -15.43% | O: -0.46% H: 0.79% C: 0.28%
financial results

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-26 (Crawled : 17:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K

Health Technology

| -20.51% | O: -6.38% H: 0.88% C: 0.88%
ALPMY | $9.46 -1.11% 500K

Manufacturing

| -18.36% | O: 0.09% H: 0.17% C: -0.3%
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -7.46% | O: 0.58% H: 1.01% C: -0.58%
keytruda bladder cancer treatment application advanced

Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -10.59% | O: 0.39% H: 0.82% C: -0.74%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| -13.6% | O: 0.22% H: 0.43% C: -0.39%
SRNE | $0.028 -8.85% 42K

Health Technology

| 0.0% | O: -63.33% H: 263.64% C: 127.27%
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -15.79% | O: 0.1% H: 0.43% C: -0.04%
AUTL | $4.8 -0.83% -0.83% 1.2M

Health Technology

| -11.96% | O: -0.91% H: 11.52% C: 4.94%
drug report t-cell global therapy market

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
GNMSF | $281.02 3.83% 210

Health Technology

| -15.94% | O: -3.69% H: 1.71% C: -2.41%
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -14.06% | O: 0.07% H: 0.88% C: -0.68%
GMAB | $28.32 -0.74% -0.74% 240K

Health Technology

| -12.94% | O: -1.1% H: 0.46% C: -0.06%
tivdak drug license review food cancer application

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -14.06% | O: 0.07% H: 0.88% C: -0.68%
BNTX | $86.19 -0.24% -0.24% 580K

Health Technology

| -22.83% | O: -2.48% H: 0.82% C: -0.37%
conference

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
Published: 2024-01-08 (Crawled : 13:30) - prnewswire.com
AZNCF | $140.15 -4.19% 560

Health Technology